Real-World Outcomes for First Line Next-Generation Hormonal Agents in Metastatic Prostate Cancer: A Systematic Review

References

• Sung H , FerlayJ, SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Kirby M , HirstC, CrawfordED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract65(11), 1180–1192 (2011).
   PubMed Web of Science ®Google Scholar
• Saad F , HotteSJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J4(6), 380–384 (2010).
   PubMed Web of Science ®Google Scholar
• Mehtälä J , ZongJ, VassilevZet al. Overall survival and second primary malignancies in men with metastatic prostate cancer. PLOS ONE15(2), e0227552 (2020).
   PubMed Web of Science ®Google Scholar
• Ning YM , PierceW, MaherVEet al. Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary. Clinical cancer research: an official journal of the American Association for Cancer Research19(22), 6067–6073 (2013).
   PubMed Web of Science ®Google Scholar
• Oncology Times . FDA Approval for Abiraterone for Treatment of Metastatic Prostate Cancer. Oncology Times33(10), 22–23 (2011).
   Google Scholar
• Ryan CJ , SmithMR, DeBono JSet al. Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England journal of medicine368(2), 138–148 (2013).
   PubMed Web of Science ®Google Scholar
• Beer TM , ArmstrongAJ, RathkopfDEet al. Enzalutamide in metastatic prostate cancer before chemotherapy. The New England journal of medicine371(5), 424–433 (2014).
   PubMed Web of Science ®Google Scholar
• Mishkin G , ValderramaA, WenL, HuN, DufourR, SimmonsS. Treatment patterns in castration-resistant prostate cancer patients with bone metastases. Journal of Managed Care and Specialty Pharmacy22(Suppl. 10-A), S23 (2016).
   Google Scholar
• Wen L , ValderramaA, CostantinoME, SimmonsS. Real-world treatment patterns in patients with castrate-resistant prostate cancer and bone metastases. American Health and Drug Benefits12(3), 142–149 (2019).
   PubMed Web of Science ®Google Scholar
• Wen L , YaoJ, ValderramaA. Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases. Journal of Managed Care and Specialty Pharmacy25, S2–S11 (2019).
   Web of Science ®Google Scholar
• Di Maio M , PerroneF, ConteP. Real-World Evidence in Oncology: Opportunities and Limitations. Oncologist25(5), e746–e752 (2020).
   PubMed Web of Science ®Google Scholar
• Berger ML , SoxH, WillkeRJet al. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf26(9), 1033–1039 (2017).
   PubMed Web of Science ®Google Scholar
• Cochrane handbook for systematic reviews of interventions [Internet]. Higgins JPT , GreenS (Eds). The Cochrane Collaboration, Version 5.1.0 [updated March 2011] (2011 [Accessed 23March2011]).
   Google Scholar
• Centre for Reviews and Dissemination . Systematic Reviews: CRD's guidance for undertaking reviews in health care [Internet]. (2009 [Accessed 23March2011]).
   Google Scholar
• Page MJ , MckenzieJE, BossuytPMet al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ372, n71 (2021).
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health . CADTH peer review checklist for search strategies [Internet]. 3 (2013 [accessed 17.7.13]).
   Google Scholar
• Sterne JA , HernánMA, ReevesBCet al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj355, i4919 (2016).
   PubMed Web of Science ®Google Scholar
• Molinier L , BauvinE, CombescureCet al. Methodological considerations in cost of prostate cancer studies: a systematic review. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research11(5), 878–885 (2008).
   PubMed Web of Science ®Google Scholar
• Brown JT , LiuY, LafolletteJA, KucukO, MooreMR, BilenMA. A risk scoring system for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line abiraterone (ABA) or enzalutamide (ENZ). Journal of Clinical Oncology. Conference38(Suppl. 6), (2020).
   Google Scholar
• Ellis LA , LafeuilleMH, GozaloL, PilonD, LefebvreP, MckenzieS. Treatment sequences and pharmacy costs of 2 new therapies for metastatic castration-resistant prostate cancer. American Health and Drug Benefits8(4), 185–195 (2015).
   PubMed Web of Science ®Google Scholar
• Freedland SJ , SchultzNM, CoutinhoADet al. Real-world analysis of prostate-specific antigen (PSA) outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA). Journal of Clinical Oncology. Conference38(Suppl. 6), (2020).
   Google Scholar
• George DJ , SartorO, MillerKet al. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. Clinical Genitourinary Cancer18(4), 284–294 (2020).
   PubMed Web of Science ®Google Scholar
• Mclain Kase A , CookC, TanW. Progression free survival in patients with castrate resistant metastatic prostate cancer: Does sequence matter?Journal of Clinical Oncology. Conference36(6 Suppl. 1), (2018).
   Google Scholar
• Nadal R , ZhangZ, RahmanHet al. Clinical activity of enzalutamide in docetaxel-naive and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate74(15), 1560–1568 (2014).
   PubMed Web of Science ®Google Scholar
• Ramaswamy K , GilliganAM, LenhartGet al. Hospitalization costs among chemotherapynaive metastatic castration-resistant prostate cancer (mCRPC) patients newly treated with enzalutamide (ENZA) or abiraterone (ABI). Journal of Clinical Oncology. Conference36(15 Suppl. 1), (2018).
   Google Scholar
• Schultz NM , FlandersSC, WilsonSet al. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis. Advances in Therapy35(10), 1639–1655 (2018).
   PubMed Web of Science ®Google Scholar
• Shore ND , SaltzsteinD, SieberPet al. Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT). Clinical Genitourinary Cancer17(6), 457–463.e456 (2019).
   PubMed Web of Science ®Google Scholar
• Tagawa ST , RamaswamyK, HuangAet al. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer and Prostatic Diseases. doi:10.1038/s41391-021-00318-3 (2021).
   Web of Science ®Google Scholar
• Wang L , DehmSM, HillmanDWet al. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Annals of Oncology29(2), 352–360 (2018).
   PubMed Web of Science ®Google Scholar
• Cavo A , RubagottiA, ZanardiEet al. Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. Therapeutic Advances in Medical Oncology10, doi: 10.1177/1758834017745819 (2018).
   PubMed Web of Science ®Google Scholar
• Cicero G , DeLuca R, BlasiLet al. Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: A retrospective study. Anti-Cancer Drugs28(9), 1047–1052 (2017).
   PubMed Web of Science ®Google Scholar
• Cicero G , DeLuca R, DorangricchiaP, DieliF. The clinical efficacy of enzalutamide in metastatic prostate cancer: Prospective single-center study. Anticancer Research37(3), 1475–1480 (2017).
   PubMed Web of Science ®Google Scholar
• Cindolo L , NatoliC, DeNunzio Cet al. Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter real life study. BMC Cancer17(1), 753 (2017).
   PubMedGoogle Scholar
• Dargenio F , CaparelloC, PacettiPet al. The treatment of metastatic castration-resistant prostate cancer (mCRPC): Initial experience within the oncology units of the department of oncology (DO) of the Azienda Toscana Nord Ovest (ATNO). Tumori105(Suppl. 6), 129–130 (2019).
   Google Scholar
• Detti B , D'angelilloRM, IngrossoGet al. Combining abiraterone and radiotherapy in prostate cancer patients who progressed during abiraterone therapy. Anticancer Research37(7), 3717–3722 (2017).
   PubMed Web of Science ®Google Scholar
• Facchini G , CavaliereC, D'anielloC, IovaneG, RossettiS. Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases: A real-world experience. Anti-Cancer Drugs30(2), 179–185 (2019).
   PubMed Web of Science ®Google Scholar
• Ferriero M , MastroianniR, DeNunzio Cet al. Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. World journal of urology38(7), 1757–1764 (2020).
   PubMed Web of Science ®Google Scholar
• Procopio G , ChiuriVE, GiordanoMet al. Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. Therapeutic Advances in Medical Oncology12, doi: 10.1177/1758835920968725 (2020).
   PubMed Web of Science ®Google Scholar
• Restelli U , CeresoliGL, CroceDet al. Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: A cost of illness study. Cancer Management and Research9, 789–800 (2017).
   PubMed Web of Science ®Google Scholar
• Sirotova Z , CourthodG, TartaroneAet al. Safety and efficacy of abiraterone in elderly patients with metastatic castration-resistant prostate cancer: Multicentric real-life experience. Anticancer Research38(4), 2531–2533 (2018).
   Web of Science ®Google Scholar
• Alibhai SMH , BreunisH, FengGet al. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 with Cognitive Function in Older Men with Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open4(7), e2114694 (2021).
   PubMed Web of Science ®Google Scholar
• Carvajal JRB , NaimiMF, ZhangL, EmmeneggerU. Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castrationresistant prostate cancer (mCRPC). Journal of Clinical Oncology. Conference39(Suppl. 6), (2021).
   Google Scholar
• Gotto G , DrachenbergDE, ChinJet al. Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC. Canadian Urological Association Journal14(12), (2020).
   Web of Science ®Google Scholar
• Hu J , AprikianAG, VanhuyseM, DragomirA. Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. Clinical Genitourinary Cancer.doi:10.1016/j.clgc.2021.08.009 (2021).
   Google Scholar
• Leibowitz-Amit R , SeahJA, AtenafuEGet al. Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. European Journal of Cancer50(14), 2399–2407 (2014).
   PubMed Web of Science ®Google Scholar
• Rocha J , AprikianAG, VanhuyseMet al. Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. CMAJ Open5(1), E265–E272 (2017).
   PubMedGoogle Scholar
• Shivji A , AliR, NorthS, SawyerM, GhoshS, ChambersC. Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. Journal of Oncology Pharmacy Practice25(6), 1293–1300 (2019).
   PubMed Web of Science ®Google Scholar
• Soleimani M , ZouK, SunderlandKet al. Effectiveness of first-line abiraterone versus enzalutamide among patients >=80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. European Journal of Cancer152, 215–222 (2021).
   PubMed Web of Science ®Google Scholar
• Wallis CJD , SatkunasivamR, SaskinRet al. Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study. Urology113, 138–145 (2018).
   PubMed Web of Science ®Google Scholar
• Woon DTS , FinelliA, CheungDCet al. A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. Urology153, 147–155 (2021).
   PubMedGoogle Scholar
• Boegemann M , KhaksarS, BeraGet al. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: Report from a large, international, real-world retrospective cohort study. BMC Cancer19(1), 60 (2019).
   PubMed Web of Science ®Google Scholar
• Chowdhury S , BjartellA, LumenNet al. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. Targeted Oncology15(3), 301–315 (2020).
   PubMed Web of Science ®Google Scholar
• Dearden L , ShaletN, ArtenieCet al. Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer. European journal of cancer care28(1), e12949 (2019).
   PubMed Web of Science ®Google Scholar
• Francini E , MontagnaniF, NuzzoPVet al. Association of Concomitant Bone Resorption Inhibitors with Overall Survival among Patients with Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate with Prednisone as First-Line Therapy. JAMA Network Open4(7), 16536 (2021).
   Web of Science ®Google Scholar
• Leval A , FlordalThelander E, KjolhedeHet al. A Retrospective Study on Patients with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Prescribed Abiraterone Acetate + Prednisone Prior to Chemotherapy in Sweden, Norway and Denmark. Value in Health21(Suppl. 3), S21 (2018).
   Google Scholar
• Payne H , RobinsonA, RappeBet al. A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. International Journal of Cancer.doi:10.1002/ijc.33845 (2021).
   PubMed Web of Science ®Google Scholar
• Thiery-Vuillemin A , PoulsenMH, LagneauEet al. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study. European Urology77(3), 380–387 (2020).
   PubMed Web of Science ®Google Scholar
• Zekri J , RamadanA, KumarM, HaggagR. Abiraterone acetate in patients with advanced castrate resistant prostate cancer: Initial real life experience in 2 cancer units. Journal of Analytical Oncology5(1), 42–46 (2016).
   Google Scholar
• Alkan A , GucZG, GurbuzMet al. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients. Journal of Men's Health17(4), 128–134 (2021).
   Web of Science ®Google Scholar
• Baillie K , MuellerT, PanJet al. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and Drug Safety29(6), 653–663 (2020).
   PubMed Web of Science ®Google Scholar
• Cesca MG , SilveiraMT, PandolfiNCet al. Comparison of enzalutamide versus abiraterone in castration-resistant prostate cancer before docetaxel: Results of a propensity score-matched analysis. Journal of Clinical Oncology. Conference37(Suppl. 15), (2019).
   Google Scholar
• Fallara G , AlverbrattC, GarmoHet al. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. Acta Oncologica.doi:10.1080/0284186X.2021.1978539 (2021).
   Web of Science ®Google Scholar
• Garcia Trevijano Cabetas M , Escario-GomezM, Gonzalez-DelValle Let al. Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most? Eur 07, 07 (2021).
   Google Scholar
• Kreis K , Horenkamp-SonntagD, SchneiderU, ZeidlerJ, GlaeskeG, WeissbachL. Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study. PharmacoEconomics - Open5(2), 299–310 (2021).
   PubMed Web of Science ®Google Scholar
• Matsubara N , YamadaY, TabataKIet al. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer16(2), 142–148 (2018).
   PubMed Web of Science ®Google Scholar
• Miyake H , HaraT, TerakawaT, OzonoS, FujisawaM. Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan. Clinical Genitourinary Cancer15(2), 313–319 (2017).
   PubMed Web of Science ®Google Scholar
• Oruc Z , KaplanMA, KaraaAMet al. Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. Future Oncology17(13), 1611–1624 (2021).
   PubMed Web of Science ®Google Scholar
• Rivero Belenchon I , MunozCalahorro C, OsmanGarcia Iet al. Quality of life (QL) in metastatic castration resistant prostate cancer (mCRPC) treated in first line with new antiandrogens (NA). European Urology, Supplements18(11), e3477–e3478 (2019).
   Google Scholar
• Romero M , VasquezE, MontoyaG, HuerfanoL. Retrospective Analysis of the Characteristics and Utilization of Health Resources in Patients with Castration Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate in Colombia. [Spanish]. Urologia Colombiana30(1), 15–22 (2021).
   Google Scholar
• Scailteux LM , CampilloB, DespasFet al. Performance of abiraterone and enzalutamide in metastatic castrationresistant prostate cancer men: A head to head comparison based on a 2014–2017 French population-based study. Fundamental and Clinical Pharmacology33(Suppl. 1), 21 (2019).
   Google Scholar
• Scailteux LM , Campillo-GimenezB, KerbratSet al. Overall Survival among Chemotherapy-Naive Patients with Castration-Resistant Prostate Cancer under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014–2018 French Population Study (the SPEAR Cohort). American Journal of Epidemiology190(3), 413–422 (2021).
   PubMed Web of Science ®Google Scholar
• Scailteux LM , DespasF, BalussonFet al. Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients. British Journal of Clinical Pharmacology.doi:10.1111/bcp.14972 (2021).
   PubMed Web of Science ®Google Scholar
• Schmidt A , AntonA, ShapiroJet al. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease. Asia-Pacific Journal of Clinical Oncology17(1), 36–42 (2021).
   PubMed Web of Science ®Google Scholar
• Serrano Domingo JJ , AlonsoGordoa T, LorcaAlvaro Jet al. The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Therapeutic Advances in Urology13, doi: 10.1177/17562872211043341 (2021).
   Web of Science ®Google Scholar
• Uchimoto T , KomuraK, FukuokayaWet al. Early prostate-specific antigen (Psa) change at four weeks of the first-line treatment using abiraterone and enzalutamide could predict early/primary resistance in metastatic castration-resistant prostate cancer. Cancers13(3), 1–12 (2021).
   Web of Science ®Google Scholar
• Abreu S , AfonsoA, PereiraIet al. Effectiveness of abiraterone acetate in elderly chemotherapy-naive patients with metastatic castration-resistant prostate cancer. European Urology, Supplements18(11), e3471 (2019).
   Google Scholar
• Alias-Melgar A , Cortez-BetancourtR, Suarez-CuencaJAet al. Abiraterone acetate use in chemotherapy-naive metastatic castration-resistant prostate cancer patients. A real-world experience at a medical center in Mexico City. [Spanish]. Revista Mexicana de Urologia79(3), (2019).
   Google Scholar
• Beardo-Villar P , Ledo-CeperoMJ, Gavira-MorenoRet al. Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer. Actas urologicas espanolas38(5), 339–345 (2014).
   PubMed Web of Science ®Google Scholar
• Fan L , DongB, ChiCet al. Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: A single-centre prospective study of efficacy, safety, and prognostic factors. BMC Urology18(1), 110 (2018).
   PubMedGoogle Scholar
• Ghiani M , MaywaldU, WilkeT, HeegB. PCN13 Comparing Trial Efficacy And Real-World Effectiveness: A Retrospective Study Of Abiraterone In Metastatic Castration Resistant Prostate Cancer Using German claims. Value in Health23(Suppl. 2), S423 (2020).
   Google Scholar
• Joshi A , ShrirangwarS, NoronhaVet al. A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. South Asian Journal of Cancer9(1), 23–26 (2020).
   PubMed Web of Science ®Google Scholar
• Koninckx M , MarcoJL, PerezI, FausMT, AlcoleaV, GomezF. Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis. Clinical and Translational Oncology21(3), 314–323 (2019).
   PubMed Web of Science ®Google Scholar
• Lin GW , LiGX, DaiBet al. Clinical activity of abiraterone plus prednisone in docetaxel-naive and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer. Asian Journal of Andrology21(2), 131–136 (2019).
   PubMed Web of Science ®Google Scholar
• Marret G , DoucetL, HennequinC, FizaziK, CulineS. Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients. Cancer Treatment and Research Communications17, 37–42 (2018).
   PubMedGoogle Scholar
• Merseburger AS , RusselC, BelzHet al. [Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naive, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy]. Aktuelle Urologie51(6), 562–571 (2020).
   PubMedGoogle Scholar
• Ni YC , ZhaoJG, ZhangMNet al. Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer. Asian journal of andrology.06 (2021).
   Web of Science ®Google Scholar
• Oyman A , BasakM, OzcelikM, OzyukselerDT, IsikS, YildirimME. Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: A real-world data analysis. Asia-Pacific Journal of Clinical Oncology17(5), e201–e207 (2021).
   PubMed Web of Science ®Google Scholar
• Poon DM , ChanK, LeeSHet al. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience. BMC Urology16, 12 (2016).
   PubMed Web of Science ®Google Scholar
• Raposo JP , BarrosCT, CaetanoFR. Abiraterone: A Single-Centre Experience. Value in Health21(Suppl. 3), S215 (2018).
   Google Scholar
• Rivero Belenchon I , MunozCalahorro C, OsmanGarcia Iet al. Switch from prednisone to dexamethasone in patients with metastatic castration resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in a multicenter study. European Urology, Supplements18(11), e3464 (2019).
   Google Scholar
• Rodriguez Antolin A , Martinez-PineiroL, JimenezRomero MEet al. Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: The Vital study. BMC Urology19(1), 92 (2019).
   PubMed Web of Science ®Google Scholar
• Sabater PS , ArcosJCT, RamonNM, DeLa Rubia Orti JE. Evaluation of the effectiveness of abiraterone in treatment of metastatic prostate cancer. [Spanish]. Revista Cubana de Farmacia49(4), (2015).
   Google Scholar
• Thortzen A , ThimS, RoderMA, BrassoK. A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. Urol34(7), 291.e291–297 (2016).
   Google Scholar
• Thurin N , RouyerM, Gross-GoupilMet al. PCN19 Effectiveness and Medical Costs of Abiraterone Acetate Versus Docetaxel in First-LINE Treatment of Metastatic Castration-Resistant Prostate Cancer from the French Nationwide Claims Database (SNDS): Camerra Study. Value in Health23(Suppl. 2), S424 (2020).
   Google Scholar
• Thurin NH , RouyerM, Gross-GoupilMet al. Impact of treatment sequence on survival outcome in patients with a second treatment line for metastatic castration-resistant prostate cancer: A new-user design in the French nationwide claims database. Pharmacoepidemiology and Drug Safety30(Suppl. 1), 249 (2021).
   Google Scholar
• Yang K , LiT, GaoZ, ZhangW. Effect of abiraterone combined with prednisone on serum CgA and NSE in metastatic castration-resistant prostate cancer without previous chemotherapy. Tropical Journal of Pharmaceutical Research18(3), 631–637 (2019).
   Web of Science ®Google Scholar
• Zhao J , ShenP, SunGet al. The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. Oncotarget8(33), 55374–55383 (2017).
   PubMedGoogle Scholar
• Zhao JG , LiuJD, ShenPFet al. Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: A real-world retrospective study. Asian Journal of Andrology20(6), 545–550 (2018).
   PubMed Web of Science ®Google Scholar
• Zhu S , ZhaoJ, NieLet al. The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer. Prostate81(15), 1191–1201 (2021).
   PubMed Web of Science ®Google Scholar
• Alghazali M , LofgrenA, JorgensenL, SvenssonM, FagerlundK, BjartellA. A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Scandinavian Journal of Urology53(5), 312–318 (2019).
   PubMed Web of Science ®Google Scholar
• Bilgetekin I , BasalFB, CinkirHY, EsinE, OksuzogluB, DemirciU. Enzalutamide treatment in metastatic castration-resistant prostate cancer: Before and after docetaxel. Journal of the College of Physicians and Surgeons Pakistan30(8), 815–821 (2020).
   PubMed Web of Science ®Google Scholar
• Ferreia Pereira F , CastroOliveira L, RosinhaAet al. Enzalutamide in metastatic castration resistant prostate cancer before chemotherapy. European Urology, Supplements18(11), e3469 (2019).
   Google Scholar
• Jung SI , KimMS, JeongCWet al. Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting. Investigative and Clinical Urology61(1), 19–27 (2020).
   PubMed Web of Science ®Google Scholar
• Kato H , FuruyaY, MiyazawaYet al. Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer. Anticancer Res36(11), 6141–6149 (2016).
   PubMed Web of Science ®Google Scholar
• Poon DMC , WongKCW, ChanTWet al. Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong. Clinical Genitourinary Cancer16(5), 402–412.e401 (2018).
   PubMed Web of Science ®Google Scholar
• Reis J , CostaI, BorgesCet al. Enzalutamide in castration-resistant metastatic prostate cancer treatment, an Oporto's center experience. European Urology, Supplements18(11), e3459 (2019).
   Google Scholar
• Ellis L , LafeuilleM, GozaloL, PilonD, LefebvreP, MckenzieS. Treatment sequences and pharmacy costs observed for abiraterone and enzalutamide: Considerations for U.S. payors. Journal of Managed Care and Specialty Pharmacy21(Suppl. 4-a), S14 (2015).
   Google Scholar
• Generic Zytiga Availability. www.drugs.com/availability/generic-zytiga.html
   Google Scholar
• Abiraterone Accord. www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-accord
   Google Scholar
• Abiraterone Mylan. www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-mylan
   Google Scholar
• Abiraterone Krka. www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-krka
   Google Scholar
• Sarri G , PatornoE, YuanHet al. Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making. BMJ Evidence-Based Medicine27(2), 109 (2022).
   PubMedGoogle Scholar
• Mccool R , FleetwoodK, GlanvilleJ, ArberM, GoodallH, NaidooS. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer. Value in Health21(10), 1259–1268 (2018).
   PubMed Web of Science ®Google Scholar
• Wei Z , ChenC, LiB, LiY, GuH. Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology11, 732599 (2021).
   PubMed Web of Science ®Google Scholar
• Mori K , MiuraN, MostafaeiHet al. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases23(4), 539–548 (2020).
   PubMed Web of Science ®Google Scholar
• Cassinello J , Dominguez-LubilloT, Gomez-BarreraMet al. Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis. Cancer Treatment Reviews93, 102152 (2021).
   PubMed Web of Science ®Google Scholar
• Grimberg F , AsprionPM, SchneiderB, MihoE, BabrakL, HabbabehA. The Real-World Data Challenges Radar: A Review on the Challenges and Risks regarding the Use of Real-World Data. Digital Biomarkers5(2), 148–157 (2021).
   PubMedGoogle Scholar
• Scher HI , MorrisMJ, StadlerWMet al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol34(12), 1402–1418 (2016).
   PubMed Web of Science ®Google Scholar
• Teo MY , RathkopfDE, KantoffP. Treatment of Advanced Prostate Cancer. Annual review of medicine70, 479–499 (2019).
   PubMed Web of Science ®Google Scholar
• Jaksa A , ArenaPJ, ChanKKW, Ben-JosephRH, JónssonP, CampbellUB. Transferability of real-world data across borders for regulatory and health technology assessment decision-making. Frontiers in Medicine9 (2022).
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence . NICE health technology evaluations: the manual. (9 February 2023), (2022).
   Google Scholar
• Wang SV , PinheiroS, HuaWet al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ372, m4856 (2021).
   PubMedGoogle Scholar